ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Jingyi Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4125-0116; OpenAlex author ID A5144320639. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper

Papers 1

Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. Co-author DOI 10.1016/j.isci.2025.112509 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Haitao Gu · 1 shared paper, 2025 · strength 0.25
- Paper Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. DOI 10.1016/j.isci.2025.112509 ↗
Qi Li · 1 shared paper, 2025 · strength 0.25
- Paper Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. DOI 10.1016/j.isci.2025.112509 ↗
Chuan Liu · 1 shared paper, 2025 · strength 0.25
- Paper Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. DOI 10.1016/j.isci.2025.112509 ↗
Long Jiang · 1 shared paper, 2025 · strength 0.25
- Paper Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. DOI 10.1016/j.isci.2025.112509 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.